Advertisement

Topics

R115777 in Treating Patients With Relapsed or Refractory Multiple Myeloma

2014-08-27 03:56:42 | BioPortfolio

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have relapsed or refractory multiple myeloma.

Description

OBJECTIVES:

- Determine the objective response rate and disease-stabilization rate in patients with relapsed or refractory multiple myeloma treated with R115777.

- Determine whether the degree of inhibition of FTase activity and farnesylation of lamin-B, H-RAS, K-RAS, and N-RAS in peripheral blood mononuclear cells (PBMC) and tumor tissue correlates with tumor response in patients treated with this drug.

- Determine whether the presence of activating RAS mutations in myeloma cells correlates with disease response in patients treated with this drug.

- Correlate R115777 plasma levels, degree of farnesylation inhibition in PBMC and tumor tissue, and RAS mutation status with tumor response in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive oral R115777 twice daily on days 1-21. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed every 4 weeks.

PROJECTED ACCRUAL: A total of 12-42 patients will be accrued for this study within 8-25 months.

Study Design

Primary Purpose: Treatment

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Intervention

chemotherapy, tipifarnib

Location

H. Lee Moffitt Cancer Center and Research Institute
Tampa
Florida
United States
33612-9497

Status

Active, not recruiting

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:56:42-0400

Clinical Trials [2052 Associated Clinical Trials listed on BioPortfolio]

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

RATIONALE: Tipifarnib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tipifarnib together with bortezomib may kill more ca...

R115777 in Treating Patients With Relapsed or Refractory Multiple Myeloma

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in t...

Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

RATIONALE: Paricalcitol may cause multiple myeloma cells to look more like normal cells, and to grow and spread more slowly. Paricalcitol may also stop the growth of the cancer cells by bl...

Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma

The purpose of this study is to test the effect of the combination of bortezomib and tipifarnib. Bortezomib (VELCADE) is approved by the Food and Drug Administration (FDA) for the treatmen...

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who...

PubMed Articles [26072 Associated PubMed Articles listed on BioPortfolio]

For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission.

The emergence of oligoclonal bands, proteins differing from those originally identified at diagnosis, has been reported in multiple myeloma patients after high-dose chemotherapy followed by autologous...

Flow Cytometric Aberrancies in Plasma Cell Myeloma and MGUS - Correlation with Laboratory Parameters.

Multiparametric flow cytometry (MFC) is a useful tool for diagnosis of plasma cell dyscrasias and assessment of minimal residual disease (MRD) in plasma cell myeloma (PCM). However, the immunophenotyp...

Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the polish multiple myeloma group.

High-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) improves the outcome of patients with multiple myeloma (MM). It seems that auto-HSCT is also a feasible thera...

Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: A case series from Korea.

Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the presence of a clonal proliferation of tumor cells. Cutaneous involvement of MM is very rare and remains poorly understood.

Automated and simplified identification of normal and abnormal plasma cells in multiple myeloma by flow cytometry.

Multiple myeloma (MM) is an incurable disease characterized by clonal plasma cell (PC) proliferation within the bone marrow (BM). Next-generation flow cytometry has become the reference tool to follow...

Medical and Biotech [MESH] Definitions

A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.

Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.

A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.

A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.

Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.

More From BioPortfolio on "R115777 in Treating Patients With Relapsed or Refractory Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Searches Linking to this Trial